Viktoria V. Dubrovskaya

Viktoria V. Dubrovskaya

Auto-generated profile, based on publicly available information

Viktoria V. Dubrovskaya

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Frontiers in Psychiatry
Verified
Journal Article
Open access
EKElena Kornetova
Elena Kornetova
AKAlexander Kornetov
Alexander Kornetov
IMIrina Mednova
Irina Mednova
VDViktoria V. Dubrovskaya
Viktoria V. Dubrovskaya
ABAnastasiia Sergeevna Boiko
Anastasiia Sergeevna Boiko
SISvetlana Ivanova
Svetlana Ivanova
Background: Metabolic syndrome (MetS) is a common problem in schizophrenia patients and associated with increased mortality due to cardiovascular disease. Second generation antipsychotics (SGAs) play an important role in facilitating MetS. Objective: The study aimed to assess weight changes and alterations of indicators of body fat composition and lipid-glucose metabolism induced by reinitiating atypical antipsychotics in patients with schizophrenia when with or without metabolic syndrome. Methods: After giving Informed Consent, newly admitted patients with a clinical diagnosis of schizophrenia (ICD-10: F20) and an age between 18 and 55 years were included. MetS was diagnosed according to International Diabetes Federation (IDF)-criteria. At entry and after 6 weeks of treatment anthropometry and biochemical analysis was carried out. Total and visceral fat were measured with the use of non-invasive bioimpedance analysis and subcutaneous fat with calculation of total adipose tissue with the use of caliperometry. Based on biochemical assessments low density (LDL) and very low-density lipoproteins (VLDL), atherogenic index and Homeostatic Model Assessment of Insulin Resistance (IR–HOMA) were calculated. Statistical analysis was conducted using Wilcoxon signed-rank test, Mann-Whitney U-test, Chi-squared test. Differences were considered statistically significant at p<0.05. Results: A total of 114 patients (59M/55F) with schizophrenia were examined; they were divided into two groups with (n=43; 37.7%) and without (n=71; 62.3%) MetS. After a 6-weeks SGA-treatment only the total fat fold, waist circumference, triglyceride level and atherogenic index underwent statistically significant changes in patients with MetS. In those without MetS statistically significant changes across all fat indicators were noted. Also, a significant increase in blood glucose and HOMA-IR parameters, triglyceride and VLDL levels and atherogenic index was observed in this group. Discussion: The study illustrates the benefits of estimating both anthropometric and biochemical parameters shortly after (re)installing treatment of schizophrenia in order to minimize the risk of MetS development.

10 September 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
EKElena Kornetova
Elena Kornetova
AKAlexander Kornetov
Alexander Kornetov
IMIrina Mednova
Irina Mednova
OLOlga A. Lobacheva
Olga A. Lobacheva
VGValeria I. Gerasimova
Valeria I. Gerasimova
SISvetlana Ivanova
Svetlana Ivanova
In this study, we aim to investigate associations between body fat parameters, glucose and lipid profiles, thyroid-stimulating hormone (TSH), and thyroid hormones (THs) levels in Tomsk-region schizophrenia patients depending upon the presence or absence of metabolic syndrome (MetS). A total of 156 psychiatric inpatients with schizophrenia who had been treated with antipsychotics for at least six months before entry were studied: 56 with and 100 without MetS. Reference groups consisted of general hospital inpatients with MetS and without schizophrenia (n = 35) and healthy individuals (n = 35). Statistical analyses were performed using the Mann–Whitney U-test, chi-square test, Spearman’s rank correlation coefficient, multiple regression analyses, and descriptive statistics. Patients with schizophrenia and MetS had significantly higher levels of free triiodothyronine (FT3) and thyroxine (FT4) compared to schizophrenia patients without MetS (3.68 [3.25; 5.50] vs. 3.24 [2.81; 3.66], p = 0.0001, and 12.68 [10.73; 15.54] vs. 10.81 [9.76; 12.3], p = 0.0001, in pmol/L, respectively). FT3 maintained an association with MetS (p = 0.0001), sex (p = 0.0001), age (p = 0.022), and high-density lipoproteins (p = 0.033). FT4 maintained an association with MetS (p = 0.0001), sex (p = 0.001), age (p = 0.014), and glucose (p = 0.009). The data obtained showed body fat parameters, glucose and lipid profiles, and THs levels in Western-Siberian schizophrenia patients depending on MetS presence or absence.

24 December 2018 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
EKElena Kornetova
Elena Kornetova
VDV. V. Dubrovskaya
V. V. Dubrovskaya
AKAlexander Kornetov
Alexander Kornetov
OLO. A. Lobacheva
O. A. Lobacheva
SISvetlana Ivanova
Svetlana Ivanova
ASArkadiy Semke
Arkadiy Semke
Objective:revealing the role of morphophenotypic indices in the development of visceral obesity in patients with schizophrenia receiving quetiapine and risperidone therapy.Materials and methods.56 indoor patients with schizophrenia who received quetiapine (n= 23) or risperidone (n= 33) at medium doses were examined. Included persons were from 18 to 65 years old with at least a 1 year history of disease, the condition of which met the criteria of schizophrenia according to ICD-10. The Basis map of sociodemographic and clinical-dynamic signs for patients with schizophrenia was filled in, PANSS in the adapted Russian version – SCI-PANSS, noninvasive bioimpedancemetry, measurement of growth, transversethoracic, biacromial and bicrystal diameter, with calculation of body mass indexes, Tanner and Rees – Eysenk and definition of integral morphophenotypic indicators were carried out. Statistical processing was performed using Student’s t-test with a preliminary estimate of Pearson’s χ2 normal distribution, the Mann – Whitney U test to compare independent samples, the Spearman correlation analysis, the two-sided Fisher test.Results.There were no significant differences in both subgroups in terms of bioimpedancemetry. The correlation between the level of visceral fat and the Rees – Eysenk index in patients receiving risperidone was a moderate inverse: the greater the value of the Rees – Eysenk index, the lower the level of visceral fat (r= –0.73381,t= –4.70833,p= 0.00015). The correlation between the Tanner index and the level of visceral fat in the quetiapine subgroup was strong: the larger the Tanner index, the higher the visceral fat level (r= 0.7763,t= 4.08481,p= 0.00181); in the risperidone subgroup, there was an average direct correlation (r= 0.48133,t= 2.39356,p= 0.02716).Conclusion.The magnitude of the Rees – Eysenk index of schizophrenic patients can be considered among other factors in the management of risperidone in individuals with asthenic physique. The determination of the Tanner index at the beginning of treatment can play the role of a prognostic factor in the development of visceral obesity in patients with schizophrenia in the planned use as a basic therapy for quetiapine.

15 November 2018 in Суицидология
Verified
Journal Article
Closed access
EKElena Kornetova
Elena Kornetova
AGAnastasya Alexandrovna Goncharova
Anastasya Alexandrovna Goncharova
AKAlexander Kornetov
Alexander Kornetov
АДА.а. Давыдов
А.а. Давыдов
ВДВ.в. Дубровская Дубровская
В.в. Дубровская Дубровская
НБН.а. Бохан
Н.а. Бохан

17 December 2021 in Psychiatry (Moscow) (Psikhiatriya)
Verified
Journal Article
Open access
PDF file
EKElena Kornetova
Elena Kornetova
VGV. I. Gerasimova
V. I. Gerasimova
AGAnastasya Alexandrovna Goncharova
Anastasya Alexandrovna Goncharova
VKV. V. Khamina
V. V. Khamina
IMIrina Mednova
Irina Mednova
SISvetlana Ivanova
Svetlana Ivanova
Background. The relevance of this work is due to the incomplete nature of existing studies on risk factors of metabolic syndrome (MS) in patients with schizophrenia. Aim: to study the MS prevalence in schizophrenia in-patients and their clinical, therapeutic and socio-demographic features. Patients and methods: 517 in-patients diagnosed with schizophrenia according to the ICD-10 criteria were examined. All patients underwent a structured clinical interview (SCID); measurement of waist circumference, blood pressure and assessment of biochemical parameters for verification of MS based on the criteria of the IDF (International Diabetes Fediration). An assessment of the severity of clinical and psychopathological symptoms was performed using the PANSS. Results: the prevalence of MS in in-patients with schizophrenia in the Western Siberia is similar to that reported in the literature. It was found that in-patients with schizophrenia and MS are characterized by a predominance of women and older age, as well as a large proportion of divorced, and a smaller proportion of never married. Women with MS were older, got longer duration of illness, and got later onset of disease than men with MS. The age of disease onset was significantly greater in patients with MS than in patients without MS. Atypical antipsychotics were more often used as the basic antipsychotic treatment in the group of patients with MS but this difference between the groups did not reach statistical significance. Conclusions: the main risk factors in patients with schizophrenia and MS coincide with risk factors of MS in general population. A later onset of the disease can act as an independent risk factor. The relationship and mutual influence of risk factors for the development of MS in patients with schizophrenia needs further study.